AIMS/HYPOTHESIS: Very low density lipoprotein (VLDL) particles are heterogeneous, comprising two main subspecies, VLDL 1 (Sf 60-400) and VLDL 2 (Sf 20-60). The aim of the study was to examine the distribution and composition of VLDL subspecies in type 2 diabetes. SUBJECTS, MATERIALS AND METHODS: We studied the composition and concentration of triglyceride-rich lipoproteins (TRLs) in 217 type 2 diabetic patients and 93 control subjects between 50 and 75 years of age. Lipoprotein subspecies were separated by density-gradient ultracentrifugation. Apolipoprotein (apo) CIII and apo E in plasma and apo CIII in TRL subspecies were measured by nephelometry and apo CII in serum by a commercial kit using a single radial immunodiffusion method. RESULTS: The concentrations of VLDL 1, VLDL 2 and intermediate density lipoprotein were significantly increased in type 2 diabetes subjects, the change being most marked for VLDL 1. There was a strong linear correlation between VLDL 1 triglycerides and plasma triglycerides in both groups (r = 0.879, p < 0.001 and r = 0.899, p < 0.001). Diabetic subjects had markedly higher plasma ratios of apo CII:apo CIII and apo CIII:apo E. Despite elevated plasma apo CIII, type 2 diabetic subjects had a relative deficiency of apo CIII in all TRL subspecies, suggesting profound disturbances of apo CIII metabolism. CONCLUSIONS/ INTERPRETATION: The elevation of VLDL 1 triglycerides is the major determinant of plasma triglyceride concentration in normal subjects and in type 2 diabetic individuals. Both apo CIII and apo E metabolism are disturbed in type 2 diabetes.
AIMS/HYPOTHESIS: Very low density lipoprotein (VLDL) particles are heterogeneous, comprising two main subspecies, VLDL 1 (Sf 60-400) and VLDL 2 (Sf 20-60). The aim of the study was to examine the distribution and composition of VLDL subspecies in type 2 diabetes. SUBJECTS, MATERIALS AND METHODS: We studied the composition and concentration of triglyceride-rich lipoproteins (TRLs) in 217 type 2 diabeticpatients and 93 control subjects between 50 and 75 years of age. Lipoprotein subspecies were separated by density-gradient ultracentrifugation. Apolipoprotein (apo) CIII and apo E in plasma and apo CIII in TRL subspecies were measured by nephelometry and apo CII in serum by a commercial kit using a single radial immunodiffusion method. RESULTS: The concentrations of VLDL 1, VLDL 2 and intermediate density lipoprotein were significantly increased in type 2 diabetes subjects, the change being most marked for VLDL 1. There was a strong linear correlation between VLDL 1 triglycerides and plasma triglycerides in both groups (r = 0.879, p < 0.001 and r = 0.899, p < 0.001). Diabetic subjects had markedly higher plasma ratios of apo CII:apo CIII and apo CIII:apo E. Despite elevated plasma apo CIII, type 2 diabetic subjects had a relative deficiency of apo CIII in all TRL subspecies, suggesting profound disturbances of apo CIII metabolism. CONCLUSIONS/ INTERPRETATION: The elevation of VLDL 1 triglycerides is the major determinant of plasma triglyceride concentration in normal subjects and in type 2 diabetic individuals. Both apo CIII and apo E metabolism are disturbed in type 2 diabetes.
Authors: R Batal; M Tremblay; P H Barrett; H Jacques; A Fredenrich; O Mamer; J Davignon; J S Cohn Journal: J Lipid Res Date: 2000-05 Impact factor: 5.922
Authors: M Guérin; W Le Goff ; T S Lassel; A Van Tol ; G Steiner; M J Chapman Journal: Arterioscler Thromb Vasc Biol Date: 2001-02 Impact factor: 8.311
Authors: J McEneny; M J O'Kane; K W Moles; C McMaster; D McMaster; C Mercer; E R Trimble; I S Young Journal: Diabetologia Date: 2000-04 Impact factor: 10.122
Authors: Helen C Looker; Marco Colombo; Felix Agakov; Tanja Zeller; Leif Groop; Barbara Thorand; Colin N Palmer; Anders Hamsten; Ulf de Faire; Everson Nogoceke; Shona J Livingstone; Veikko Salomaa; Karin Leander; Nicola Barbarini; Riccardo Bellazzi; Natalie van Zuydam; Paul M McKeigue; Helen M Colhoun Journal: Diabetologia Date: 2015-03-05 Impact factor: 10.122
Authors: Gaia Botteri; Marta Montori; Anna Gumà; Javier Pizarro; Lídia Cedó; Joan Carles Escolà-Gil; Diana Li; Emma Barroso; Xavier Palomer; Alison B Kohan; Manuel Vázquez-Carrera Journal: Diabetologia Date: 2017-08-23 Impact factor: 10.122
Authors: A Hiukka; E Leinonen; M Jauhiainen; J Sundvall; C Ehnholm; A C Keech; M R Taskinen Journal: Diabetologia Date: 2007-07-26 Impact factor: 10.122
Authors: M Adiels; M-R Taskinen; C Packard; M J Caslake; A Soro-Paavonen; J Westerbacka; S Vehkavaara; A Häkkinen; S-O Olofsson; H Yki-Järvinen; J Borén Journal: Diabetologia Date: 2006-02-04 Impact factor: 10.122
Authors: O Olivieri; N Martinelli; A Bassi; E Trabetti; D Girelli; F Pizzolo; S Friso; P F Pignatti; R Corrocher Journal: Clin Exp Med Date: 2008-01-11 Impact factor: 3.984
Authors: Nicki Tiffin; Euan Adie; Frances Turner; Han G Brunner; Marc A van Driel; Martin Oti; Nuria Lopez-Bigas; Christos Ouzounis; Carolina Perez-Iratxeta; Miguel A Andrade-Navarro; Adebowale Adeyemo; Mary Elizabeth Patti; Colin A M Semple; Winston Hide Journal: Nucleic Acids Res Date: 2006-06-06 Impact factor: 16.971